Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.

Haby Henary, Razelle Kurzrock, G. S. Falchook, Aung Naing, Stacy L. Moulder, Jennifer J. Wheler, Apostolia M. Tsimberidou, Jean‐Bernard Durand, Pengxia Yang, Mary Johansen,

Journal of Clinical Oncology · 2011 · 13 citations · 0 references

Concepts

Abstract

3023 Background: PBI-05204 (Oleandrin), a cardiac glycoside, inhibits the α-3 subunit Na-K ATPase pump. Relative expression of the α-3 subunit in tumor cells correlates with proliferation. Oleandrin inhibits FGF-2 export, activation of NF-Kβ, phosphorylation of Akt, p70S6K, decreasing mTOR activity. In this first-in-human study, we sought to determine the MTD/recommended phase II dose and to define the pharmacokinetics (PK) and pharmacodynamics (PD) of PBI-05204 in advanced cancer patients (pts). Methods: Trial was a 3+3 phase I design. PBI-05240 was given for 21 of 28 days. Dose was increased by 100% if no related grade 2 adverse event (AE) emerged and increased by 50% if a grade 2 AE occurred. Blood samples were drawn for PK and drug-mediated changes in pAkt, p70S6K, and S6 (mTOR effectors) expression in peripheral blood mononuclear cells (PBMCs) for PD analysis. Results: 46 pts were dosed at 8 dose levels (DL) of PBI-05204 (0.6 to 10.2 mg/day). 2 dose-limiting toxicities occurred at DL 8 (grade 3 proteinuria,fatigue) thus the MTD was DL7. Most common AEs were fatigue (56.1%), abdominal pain (41.5%), constipation (41.5%), nausea (41.5%), and diarrhea (39.0%). Cardiac disorders were reported in 10 pts (24.4%), all grade 1, except for 1 pt with grade 2 SVT. Of the 45 evaluable pts, 7 had stable disease for > 4 months, with bladder, colorectal, fallopian tube, breast, appendecal and pancreatic carcinoma (2 pts). Dose dependent mean peak concentrations as high as 2 ng/mL were achieved. Mean AUC: 5 – 36 μg/L*hr across DLs with a half-life range of 6-14 hrs. Western blot analysis of PBMCs showed markedly reduced phosphorylation of Akt, p70S6K, and S6 in a time dependent manner in 7 pts (1 at DL 2, 3, 1 at DL 5 and 2 at DL 6). Reduction of these effectors was concomitant with higher levels of Na, K-ATPase aƒ{3 subunit expression. In these pts, results of proteomic array analysis showed other oncogenic pathways-NFkB, VEGF and STAT5 were down regulated after 21 days on study. Conclusions: PBI-05204 is well tolerated up to 10.2/mg/day with very little AEs or cardiotoxicity. Initial PD analysis suggesting target effect.